130,296 members

Skip to content. | Skip to navigation


Help wanted


Is anyone working with Blue Teq

Up to Help wanted
August 26. 2016
Sam Coombes

I work for an acute NHS trust and would like to discuss with anyone who is implementing Blue Teq to try and establish what issues people are having or have had.

August 30. 2016
Danny Roberts

If you mean the system commonly used to manage Low Priority Procedures or High Cost Drugs then yes it's implemented in my current and previous organisations.  Common feedback is that it is an increased burden for clinicians but that seems to subside once people work it into their clinical practice.  I'm not aware of any underlying technical problems or usability issues.

August 30. 2016
Sam Coombes


Thank you so much for getting back to me . Do you know anyone currently working on this

As I have a question about Blue Teqs technical side. Do trusts in your experience now refer there out of area patients to the CCG corresponding to their post code? If not does the Trust just except that it will have to pay for those patients coming from outside of the area and potentially not receive payment. This is a situation I for see at the moment as there is currently no parity on form design and approval criteria.

I hope that makes sense.



August 31. 2016
Patrick Wilson

Hi Sam,


Every Trust that has use of drugs through the Cancer Drugs Fund will be using Blueteq (to request prior approval for CDF drugs) or that has a contract for specialist services with NHS England (to request prior approval of specific high cost drugs eg MS, Hep C, Asthma, IPF, Cancer outside the CDF.).


The use of Blueteq via CCGs is patchy. Some CCGs are mandating it, some are not. It is a commissioner tool and therefore commissioner mandated usually. Not sure if I understand the second question. Are you asking about a situation where a provider Trust has been required to use Blueteq by some but not all of the CCGs that commission its services? I think from a service perspective they either use Blueteq or not, you can't have the clinicians trying to figure out which CCG a patient is from and whether they need to submit or not. I would suggest whoever the lead local commissioner is dictates whether Blueteq is used. Here our local CCGs aren't using Blueteq. If a neighbouring county's CCG was using it for a given area (say for biologics in rheumatology) I wouldn't expect our rheumatologists to have to complete a Blueteq submission for patients from that CCG specifically unless it was in our contract.


Not sure if that helps

Patrick (a pharmacist)

September 01. 2016
ellen sinden


Blueteq has been used in my trust for CDF (we have the Dorset Cancer Centre so our chemo use is high). We have HAD to start using it for Omalizumab (asthma), MS, Palivizumab (paeds) and non CDF chemo as part of our contract with NHSE- we are not a commissioned hep C centre or IPF so don't issue these types of drugs.

Our CCG doesn't use blueteq and we are still using paper notification forms for high cost drugs such as the biologics.

The Blueteq system itself is very simple although I havent had to design any forms for the system- they have been provided by NHSE (some CCG or NHSE embedded pharmacists have been involved in this). I think there is generally the concern that it is going to take too long but once the system has been accessed and tried the forms are a tick box so very quick to complete. Most of the time is spent logging in and resetting passwords as clinicians/nurses often forget them! The MS nurses are used to completing paper notification forms so to switch to electronic systems has been quicker for them- it also gives an instant approval letter that can be put into the patient notes or sent to the patients GP.

The people who have mostly complained about the system are those that never completed paper notification forms (& they should be done but was never enforced!) and those using the drug outside of NICE or commissioned guidance - it has therefore helped to flush this practice out but of course creating animosity amongst the clinicians!

The major issue I have with it is when we have a patient transferred to us either from out of area or as part of shared care with a specialist centre e.g. Omalizumab should be initiated at a commissioned specialist asthma centre and put under shared care once stabilised- our local specialist centre is in dispute with NHSE about using blueteq  but even if they did there is no way of accessing the competed forms that another trust has completed. There is no formalised shared care process between specialist centres and smaller trusts e.g. DGHs but I think a blueteq form should be part of this process so it covers the DGH financially for the drug. The other issue is whether it is cross charged back to the specialist centre or to NHSE direct and again this is very 'woolly'

In general it isn't a bad system but to get clinician engagement may be an issue- I'm so looking forward to the fast approaching palivizumab season for the second year of using Blueteq (?)- last year things didn't go very smoothly!

hope this helps


September 09. 2016
Sam Coombes

 Hi Ellen,

Firstly apologies for not responding to you sooner. This is extremely helpful thank you very much. We are just working out our go live strategy for none CDF. In your experience how time consuming has this been. Has the Blue teq system thus far used up more time and where have you found the savings to be. 

Kind Regards


Pharmacy Tech

May 25. 2018
Mosan Ashraf
Hi Sam, it may be too late. Do you still need any help with this? I helped implement Blueteq at a NHS trust for CCG non-PBR High cost drugs
December 03. 2018
Mark Haffner
If help is still needed I have been managing BlueTeq for the CDF since 2013, more than happy to help
Quick reply
Post anonymously
Powered by Ploneboard